This website is intended only for United States healthcare professionals; if you are not a United States healthcare professional, please visit www.BioMarin.com
This website was developed and funded by BioMarin and is intended for healthcare professionals only. It offers a non-exhaustive selection of materials, including but not limited to publications, presentations, posters and educational materials, to support scientific exchange.
Clinical study results reflect knowledge at the study’s completion and may not be current. Review the methodology, limitations, and authors’ financial disclosures for details.
The information on this website is not medical advice and should not replace independent medical judgment or further research. Content on investigational therapeutics or uses of approved products does not confirm safety or efficacy. BioMarin does not endorse off-label use of its medicines.
As product information may vary by country, please refer to your local health authority regulations and respective approved product information for indications and safety details.

Search

Congress Posters & Presentations

Access MPS related posters and presentations from recent congresses.

Mucopolysaccharidosis (MPS)

Filter
Filter by:
Filter by congress:
Filter by year:
Reset all filters
Cancel

Congress Posters and Presentations

Access posters and presentations from recent congresses. All displayed posters and presentations are protected by copyright and are intended for individual use only.
Please Note: Poster content may be unavailable or delayed. This could be due to copyright or embargo guidelines.
You may check back later or contact medinfo@bmrn.com or complete a request form to inquire about this specific material

Poster

View content

  • Congresses
  • MPS IVA
  • WORLDSymposium

Improvements in quality of life outcomes among individuals with MPS IVA treated with elosulfase alfa: results from the Morquio A Registry Study (MARS)

View content

Poster

View content

  • Congresses
  • MPS IVA
  • The Professional Society for Health Economics & Outcomes Research Europe (ISPOR-EU)
  • 2025

Psychometric validation of the Mucopolysaccharidosis Health Assessment Questionnaire (MPS-HAQ) for mucopolysaccharidosis IVA

View content

Poster

View content

  • Congresses
  • MPS IVA
  • WORLDSymposium
  • 2025
  • Real World Evidence
  • Safety and Efficacy Profile

Long-term outcomes of MPS IVA patients treated with elosulfase alfa: Findings from the Morquio A Registry Study (MARS) after 10 years

View content

Poster

View content

  • Congresses
  • MPS IVA
  • WORLDSymposium
  • 2024
  • Real World Evidence
  • Safety and Efficacy Profile

Enzyme replacement therapy is associated with improved endurance in MPS IVA patients at different ages

View content

Poster

View content

  • Congresses
  • MPS IVA
  • WORLDSymposium
  • 2024
  • Genetic Testing & Diagnosis

Skeletal dysplasia gene panel with integrated enzyme follow-up for the diagnosis of lysosomal storage disorders: MPS IVA case series

View content

Poster

View content

  • Congresses
  • MPS IVA
  • MPS VI
  • American College of Medical Genetics & Genomics (ACMG)
  • 2023
  • Genetic Testing & Diagnosis

Gene panels for skeletal dysplasia and epilepsy: Maximizing clinical utility through careful design, regular review, and clinician-laboratory collaboration

View content

Poster

View content

  • Congresses
  • MPS IVA
  • WORLDSymposium
  • 2023
  • Real World Evidence
  • Safety and Efficacy Profile

Real-World Impact of Enzyme Replacement Therapy on Endurance in Patients with MPS IVA

View content

Presentation

View content

  • Congresses
  • MPS IVA
  • WORLDSymposium
  • 2022
  • Real World Evidence
  • Safety and Efficacy Profile

Long-term outcomes of MPS IVA patients treated with elosulfase alfa: Findings from the Morquio A Registry Study (MARS) after 6 years

View content

Poster

View content

  • Congresses
  • MPS IVA
  • MPS VI
  • American College of Medical Genetics & Genomics (ACMG)
  • 2022
  • Genetic Testing & Diagnosis

Clinical utility of a sponsored, no-charge skeletal dysplasia gene panel testing program: Results from >2600 tests

View content

Poster

View content

  • Congresses
  • MPS IVA
  • Society for the Study of Inborn Errors of Metabolism (SSIEM)
  • 2022
  • Real World Evidence
  • Safety and Efficacy Profile

Long-Term Outcomes in Adults with MPS IVA Treated with Elosulfase Alfa: Findings from the Morquio A Registry Study

View content

Poster

View content

  • Congresses
  • MPS IVA
  • MPS VI
  • WORLDSymposium
  • 2021
  • Genetic Testing & Diagnosis

Clinical Utility of a Sponsored, No-cost Skeletal Dysplasia Gene Panel Testing Program: Results from 850 Tests

View content

Poster

View content

  • Congresses
  • MPS IVA
  • WORLDSymposium
  • 2021
  • Genetic Testing & Diagnosis

Molecular Basis of Mucopolysaccharidosis IVA (Morquio A Syndrome): A Review and Classification of GALNS Gene Variants and Reporting of New Variants

View content